Clinical trials: Esophagogastric Junction
Gastroesophageal Adenocarcinoma
RESTAGE (REpurposing STAtins to Improve Outcomes in GastroEsophageal Cancer) Trial
Esophageal and gastroesophageal junction cancers are serious diseases with limited cure rates, even when patients receive chemotherapy and surgery. New ways to improve treatment are urgently needed.
- Trial name
- RESTAGE (NCT07625930)
- Testing
- FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel), Simvastatin, Durvalumab
- Where
- Canada
- Volunteers
- 184 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
HER2-negative, Gastroesophageal Junction
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas
The goal of this clinical study is to learn more about the study drug, Denikitug (DEN, GS-1811), to evaluate the efficacy and safety of Denikitug Monotherapy and Denikitug-based combinations in in participants with human…
- Conditions
- HER2-negative, Gastroesophageal Junction, Esophageal Adenocarcinoma, Gastric Adenocarcinoma
- Trial name
- NCT07546812
- Testing
- Denikitug, Nivolumab, Ramucirumab
- Where
- 15 sites in United States, Australia and 3 more
- Volunteers
- 120 people
- Sponsor
- Gilead Sciences
Adenocarcinoma - GEJ, Adenocarcinoma of the Stomach
A Study of HER2 Tumor Vaccine in Patients With Her-2 Positive Gastric/GEJ Adenocarcinoma Esophagogastric
This is a single-arm, open-label, clinical study to evaluate the safety of HER2 tumor vaccine injection alone/in combination with standard of care chemotherapy in patients with HER2/neu overexpressing gastric or gastroesophageal…
- Trial name
- NCT05315830
- Testing
- HER2 Tumor Vaccine, HER2 Tumor Vaccine+ Standard of Care chemotherapy
- Where
- China
- Volunteers
- 10 people
- Sponsor
- The First Affiliated Hospital of Bengbu Medical University
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
The main objective of this study is to compare efficacy of bemarituzumab combined with oxaliplatin, leucovorin, and 5-fluorouracil (5-FU) (mFOLFOX6) to placebo plus mFOLFOX6 as assessed by overall survival (OS) in participants…
- Trial name
- FORTITUDE-101 (NCT05052801)
- Testing
- Bemarituzumab, mFOLFOX6
- Where
- 300 sites in United States, Argentina and 35 more
- Volunteers
- 547 people
- Sponsor
- Amgen
Cancer of Stomach, Gastroesophageal Cancer
Efficacy of Pegamotecan (PEG-Camptothecin) in Localized or Metastatic Cancer of the Stomach or Gastroesophageal Junction
The purpose of this study is to evaluate the safety and efficacy of pegamotecan (PEG-camptothecin) in patients with pathologically-diagnosed locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal…
- Trial name
- NCT00080002
- Testing
- Pegamotecan
- Sponsor
- Enzon Pharmaceuticals, Inc.
Advanced Solid Tumor, Metastatic Solid Tumor
A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
This is a Phase 1 study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PRT7732 in patients with select advanced or metastatic solid tumors with a SMARCA4 mutation.
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Carcinoma, SMARCA4 Mutation
- Trial name
- NCT06560645
- Testing
- PRT7732
- Where
- 28 sites in United States, Australia and 4 more
- Volunteers
- 42 people
- Sponsor
- Prelude Therapeutics Incorporated
Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma
SHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer
To evaluate the effectiveness and safety of SHR-A1811 combined with apatinib in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma and colorectal cancer.
- Conditions
- Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Colorectal Cancer
- Trial name
- NCT06666166
- Testing
- SHR-A1811 & Apartinib
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Yunpeng Liu
Gastric Cancer, Gastroesophageal Junction Cancer
MRI and CT in Gastroesophageal Junction or Upper Gastric Adenocarcinoma
Accurate preoperative Siewert classification, precise assessment of the extent of esophageal involvement, and staging is crucial for determining the appropriate surgical approach and achieving negative resection margins.
- Trial name
- NCT06640153
- Testing
- mpMRI
- Where
- China
- Volunteers
- 100 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Esophageal Cancer, Gastric Cancer
A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma
Patients can be prescreened for the study at the time of diagnosis of locally advanced or metastatic disease by determining presence of LOH high status and/or deleterious alterations in HR pathway genes in the most recent…
- Conditions
- Esophageal Cancer, Gastric Cancer, Adenocarcinoma
- Trial name
- NCT03840967
- Testing
- Niraparib
- Where
- 4 sites in United States
- Volunteers
- 14 people
- Sponsor
- Shadia Jalal, MD
HER-2 Gene Amplification, Esophagus Cancer
A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach
To determine whether the combination of MM-111 plus paclitaxel and trastuzumab is more effective than paclitaxel and trastuzumab alone
- Conditions
- HER-2 Gene Amplification, Esophagus Cancer, Gastroesophageal Junction Cancer, Stomach Cancer
- Trial name
- NCT01774851
- Testing
- MM-111, Paclitaxel, Trastuzumab
- Where
- 21 sites in United States
- Volunteers
- 84 people
- Sponsor
- Merrimack Pharmaceuticals
Gastric Cancer, GastroEsophageal Cancer
A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer
The purpose of this trial is to estimate overall response rate (ORR) of SHR-1210 combined with capecitabine and oxaliplatin or with apatinib as first-line treatment in subjects with locally advanced or metastatic gastric or…
- Trial name
- NCT03472365
- Testing
- SHR-1210, Capecitabine, Oxaliplatin
- Where
- China
- Volunteers
- 67 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Esophageal Adenocarcinoma (UICC TNM7), Adenocarcinoma of the Esophagogastric Junction
Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus
The trial is designed to investigate differences in outcome of patients with esophageal adenocarcinoma and junctional adenocarcinoma treated with perioperative (neoadjuvant + adjuvant) chemotherapy (FLOT) plus surgical resection…
- Trial name
- ESOPEC (NCT02509286)
- Testing
- 5-Fluorouracil, Leucovorin, Oxaliplatin
- Where
- 30 sites in Germany
- Volunteers
- 438 people
- Sponsor
- University Hospital Schleswig-Holstein
Stretta Device
Stretta Treatment in GERD After SG
To evaluate the effect and explore the mechanism of action behind the potential effect of Stretta® on GERD after SG.
- Trial name
- Stretta (NCT05094895)
- Testing
- Stretta
- Where
- Belgium
- Volunteers
- 60 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Gastric Cancer, GastroEsophageal Cancer
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Cohort 1 [CLOSED] Study treatment involves two segments: (1) Induction Immunotherapy segment with pembrolizumab monotherapy every 3 weeks until irRECIST PD and (2) Combination Therapy segment.
- Conditions
- Gastric Cancer, GastroEsophageal Cancer, Adenocarcinoma
- Trial name
- SEQUEL (NCT04069273)
- Testing
- Pembrolizumab Monotherapy, Ramucirumab, Paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 58 people
- Sponsor
- Harry H Yoon
Gastric Cancer, Pancreatic Cancer
Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression
This is an open label, multi-center, Phase 1 clinical trial to evaluate the safety and efficacy of autologous claudin18.2 chimeric antigen receptor T-cell therapy in advanced solid tumors with positive CLDN18.2 expression
- Conditions
- Gastric Cancer, Pancreatic Cancer, Advanced Ovarian Carcinoma, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT05472857
- Testing
- Claudin 18.2 CAR-T
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Suzhou Immunofoco Biotechnology Co., Ltd
Gastric or Gastroesophageal Junction Adenocarcinoma
Adjuvant Therapy for Potentially Immunotherapy-Responsive Gastric or Gastroesophageal Junction Adenocarcinoma
This study evaluates the clinical efficacy and safety benefits of immunotherapy in a selected patient population by comparing serplulimab combined with short-course SOX regimen versus SOX regimen alone as adjuvant therapy for…
- Trial name
- ALTER-SOX (NCT07772557)
- Testing
- Standard Treatment Group: SOX regimen for up to 6 cycles Oxaliplatin: 130 mg/m², i.v., D1, Q3W; S-1 (Tegafur-Gimeracil-Oteracil Potassium): Oral administration: 40 mg per dose for BSA < 1.25, 50 mg pe, Experimental Immunotherapy Group: Phase I: Combination Therapy Period (First 3 Cycles) Oxaliplatin: 130 mg/m², intravenous infusion, Day 1, every 3 weeks (Q3W), for 3 cycles. Serplulimab: 300 mg, i
- Volunteers
- 108 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Esophageal Cancer, Malignant Neoplasm of Cardio-esophageal Junction of Stomach
Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy for Resectable Esophageal Cancer
The purpose of this study is to see whether giving azacitidine before each cycle of chemotherapy prior to surgery is safe.
- Trial name
- VEOX (NCT01386346)
- Testing
- Azacitidine, Oxaliplatin, Epirubicin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Weill Medical College of Cornell University
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Relationship Between Perioperative Treatment Efficacy and The Tumor Microenvironment for Locally Advanced Resectable Gastric Cancer.
Perioperative drug treatment has gradually become the standard regimen for locally advanced gastric cancer, whereas only a subset of patients could benefit from it.
- Trial name
- NCT04850729
- Testing
- non-intervention
- Where
- China
- Volunteers
- 169 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Gastroesophageal Junction Adenocarcinoma, Malignant Neoplasm of the Cervical Esophagus
Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-III Esophageal Cancer
This phase I trial studies the side effects and best dose of ganetespib when given together with paclitaxel, carboplatin, and radiation therapy in treating patients with stage II-III esophageal cancer.
- Conditions
- Gastroesophageal Junction Adenocarcinoma, Malignant Neoplasm of the Cervical Esophagus, Malignant Neoplasm of the Thoracic Esophagus, Stage IIA Esophageal Cancer AJCC v7
- Trial name
- NCT02389751
- Testing
- Carboplatin, Ganetespib, Paclitaxel
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Gastric or Gastroesophageal Junction Adenocarcinoma
Neoadjuvant SHR-A1811 and SHR-A1701 ± Pertuzumab for Potentially Immunotherapy-Sensitive GC or GEJ Adenocarcinoma
This is a prospective, single-center, randomized controlled phase II clinical trial.It plans to enroll a total of 24 eligible patients with locally advanced gastric/gastroesophageal junction adenocarcinoma who are HER2-positive…
- Trial name
- NCT07716111
- Testing
- Trastuzumab Rezatecan and Retlirafusp alfa, Trastuzumab Rezatecan and Retlirafusp alfa+Pertuzumab
- Where
- China
- Volunteers
- 24 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.